title: New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
abstract: Pancreatic cancer is a lethal disease and its prognosis remains dismal. The modest results of existing available treatments in the second line setting reveal the need of new therapeutic strategies. In this year's American Society of Clinical Oncology (ASCO) Annual Meeting two remarkable trials and one retrospective analysis were presented regarding this vulnerable group of patients. According to the published results, docetaxel plus oxaliplatin (Abstract #4034), selumetinib plus erlotinib (Abstract #4014) and nab-paclitaxel (Abstract #e15057) have shown promising efficacy and manageable toxicity that should be elucidated and confirmed by new prospective, large, randomized trials.
authors.affiliation: University of Pittsburgh Cancer Institute. Pittsburgh, PA, USA.
authors.forename: Vasilis Stefanos
authors.initials: VS
authors.lastname: Ramfidis
authors.forename: Kostas N
authors.initials: KN
authors.lastname: Syrigos
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D006801:Humans; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011799:Quinazolines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; C517975:AZD 6244; D000418:Albumins; D001562:Benzimidazoles; D009944:Organoplatinum Compounds; D011799:Quinazolines; D043823:Taxoids; D000077150:Oxaliplatin; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D017239:Paclitaxel